Anti-CCR8 Antibody Demonstrates Promising Results for Gastric Cancer
By Nataliya Uboha, MD, PhD, Thomas Karasic, MD - Last Updated: March 19, 2025Nataliya Uboha, MD, PhD, of the University of Wisconsin School of Medicine and Public Health, and Thomas Karasic, MD, of the University of Pennsylvania, discuss a new approach to treating advanced gastric cancer with an antibody targeting CCR8, a protein on immune cells in the tumor microenvironment.
Advertisement
Advertisement
Related Posts
Dr. Cytryn considers two studies evaluating PD-1 inhibition in patients with MSI-high tumors in the locally advanced setting.
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.